Sign In

Melatonin-Shikonin Combination Reported as a Novel Drug Candidate for Advanced Chemotherapeutic Regimens

September 2020 Dr. Jibran Sualeh Muhammad from the College of Medicine conducted a research study in collaboration with the University of Toyama and the University of Fukui in Japan. This study reported that Melatonin, an endogenous hormone, and a natural supplement, greatly sensitizes cancer cells to the toxic effect of Shikonin. Hence, the Melatonin-Shikonin combination was reported as a novel drug candidate for advanced chemotherapeutic regimens.


Back to list